Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by ready2go1on Mar 13, 2011 8:24pm
260 Views
Post# 18278838

positive article

positive articleits a shame that share price does not react to any of the news coming out

https://www.msnbc.msn.com/id/42034218/ns/health-cancer/

by way Immunology Device Panel meeting is tentatively schedulled for March 31st. You can get daily updates by going to the FDA site. Next one is in June but I am not positive. They should give at least 15 day notice but I would think that share price would move weeks in advance so I do not expect a meeting or pca3 to be on the agenda (just a guess)

EAU is March 18 to 21 I will post abstracts on the next post.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities